Clinical Trials Browser

Recruiting × OTHER_GOV × Ovarian Neoplasms × Clear all

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05236686 2025-11-19

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Phase NA Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Lymphatic Metastasis, Ovarian Neoplasms

NCT07171528 2025-09-12

KOV-02S

Phase 2 Recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT07169396 2025-09-11

GEN_EXP_CO2021

Ovarian Neoplasms

NCT06839144 2025-07-11

OC-POP-PT

Phase 2 Recruiting

Neoplasms, Ovarian Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04846933 2025-01-16

DECIDER

Phase NA Recruiting

Ovarian Neoplasms

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 Recruiting

GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms